KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Payables (2016 - 2025)

Historic Payables for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $94.0 million.

  • Sarepta Therapeutics' Payables fell 2084.55% to $94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.0 million, marking a year-over-year decrease of 2084.55%. This contributed to the annual value of $214.4 million for FY2024, which is 3002.95% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Payables is $94.0 million, which was down 2084.55% from $136.7 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Payables high stood at $214.4 million for Q4 2024, and its period low was $44.2 million during Q3 2021.
  • For the 5-year period, Sarepta Therapeutics' Payables averaged around $104.6 million, with its median value being $95.9 million (2022).
  • Within the past 5 years, the most significant YoY rise in Sarepta Therapeutics' Payables was 18821.58% (2021), while the steepest drop was 4074.31% (2021).
  • Over the past 5 years, Sarepta Therapeutics' Payables (Quarter) stood at $76.7 million in 2021, then increased by 24.93% to $95.9 million in 2022, then soared by 72.01% to $164.9 million in 2023, then skyrocketed by 30.03% to $214.4 million in 2024, then crashed by 56.16% to $94.0 million in 2025.
  • Its Payables stands at $94.0 million for Q3 2025, versus $136.7 million for Q2 2025 and $156.1 million for Q1 2025.